In blastocyst chimeras, embryonic stem (ES) cells contribute to embryonic tissues but not extraembryonic trophectoderm. Conditional activation of HRas1 Q61L in ES cells in vitro induces the trophectoderm marker Cdx2 and enables derivation of trophoblast stem (TS) cell lines that, when injected into blastocysts, chimerize placental tissues. Erk2, the downstream effector of Ras-mitogen-activated protein kinase (MAPK) signaling, is asymmetrically expressed in the apical membranes of the 8-cell-stage embryo just before morula compaction. Inhibition of MAPK signaling in cultured mouse embryos compromises Cdx2 expression, delays blastocyst development and reduces trophectoderm outgrowth from embryo explants. These data show that ectopic Ras activation can divert ES cells toward extraembryonic trophoblastic fates and implicate Ras-MAPK signaling in promoting trophectoderm formation from mouse embryos.
The blastocyst is the first embryonic stage with anatomical distinction of more than one cell type-the inner cell mass (ICM) and trophectoderm (TE). ICM and TE cells have distinct fates and do not transdifferentiate when transplanted to ectopic positions in the embryo 1 . Embryonic stem cells derive from the ICM and can differentiate into all tissue lineages of the adult. The TE-derived trophoblastic stem cells 2 contribute exclusively to the extraembryonic trophoblastic tissues of the placenta. The hypoblast of mature blastocysts gives rise to extraembryonic endoderm stem cells, which generate parietal and visceral endoderm 3 . These three stem cell types each express transcription factors that mark the segregation of these lineages: Oct4 and Nanog in ES cells, Cdx2 in TS cells and Gata6 in extraembryonic endoderm cells. The signaling pathways that segregate these lineages remain poorly defined. Here we show that expression of an activated Ras allele and growth in selective culture conditions diverts ES cells from embryonic to trophoblastic fates. Furthermore, inhibition of MAPK compromises trophectoderm function in mouse embryos and outgrowth of trophoblastic tissue in explant cultures, implicating Ras-MAPK signaling in the regulation of the emergence of extraembryonic cell lineages in early development.
We originally set out to test the hypothesis that expression of an activated Ras gene might complement Myc and telomerase function to induce malignant transformation in ES cells, in agreement with classical oncogene cooperation models 4, 5 . We engineered the mouse ES cell line Ainv15 (ref. 6 ) to express an activated Ras allele (Hras1 Q61L ) in a doxycycline-inducible manner (iRasES cells; Fig. 1a,b) . We tested the effect of Ras activation on tumor formation of iRasES cells in immune-deficient mice (Rag2 À/À ; gamma c À/À ), by adding doxycycline to the drinking water 7 . In control animals not given doxycycline, the iRasES cells formed large, well-differentiated benign teratomas (Fig. 1c,d ). In contrast, animals fed doxycycline succumbed rapidly (beginning 12 days after cell inoculation) to aggressive tumors with massive internal hemorrhage (Fig. 1e) . Tumor histology revealed giant cells with glycogen-containing inclusion bodies 8 ( Fig. 1f-h ), consistent with choriocarcinoma, a malignancy of proliferating trophoblast. Notably, developing mouse embryos that express HRas have previously been shown to induce tumors of extraembryonic trophectodermal tissue 9 .
Teratomas formed from uninduced iRasES cells expressed markers of the embryonic germ layers but not of differentiated trophectodermal tissues, whereas the tumors that formed following Ras induction lacked markers of embryonic germ layers and instead expressed markers of spongiotrophoblast (trophoblast specific protein a, Tpbpa; placental lactogen 1, Prl3d1) and primary and secondary giant cells (placental alkaline phosphatase, Plac1l; proliferin, Prl2c2; Fig. 1i ). These data confirm that Ras activation in ES cells promotes differentiation into trophectodermal lineages that typically are not observed in teratomas formed from ES cells. We failed to observe tumor formation following injection of embryo-derived TS cells into immune-deficient mice (n ¼ 10), thereby demonstrating that TS cells behave differently than ES cells with Ras activation.
Given the multiple trophoblast cell types in Ras-induced tumors, we reasoned that activation of Ras signaling might prompt ES cells to transdifferentiate through a TS cell intermediate. When cultured in medium containing leukemia inhibitory factor (LIF), iRasES cells expressing activated Ras eventually formed flattened colonies of epithelial-like cells (Fig. 2a) . When LIF was removed, the cells differentiated into trophoblastic giant cells (Fig. 2b ) and syncytial trophoblasts (Fig. 2c) . Replacement of LIF with Fgf4 in ES cell culture maintained the colony morphology of ES cells (Fig. 2d) . However, Ras induction coupled to culture in Fgf4 and heparin, media conditions that promote isolation of TS cells from blastocysts, produced flat colonies (Fig. 2e) that closely resembled blastocyst-derived TS cells (Fig. 2f) . We call them ES-TS cells.
We observed that transdifferentiation of ES into ES-TS cells was robust, occurring in essentially all cells (Supplementary Note online). In contrast, reversion of established TS cells back to an ES-like phenotype by withdrawal of Ras induction occured rarely: we obtained one revertant clone out of 10 À7 cells seeded in doxycycline-free media, suggesting that the differentiation of ES cells into TS cells involves mechanisms of tight and largely irreversible epigenetic restriction.
We labeled the parental iRasES cells or the clonal ES-TS cells with the fluorescent dye pKH26, and injected them into 4-to 8-cell-stage mouse embryos to follow their fate in blastocyst chimeras. At day 3.5, iRasES cells were found within the ICM (Fig. 2g) , whereas ES-TS cells (Fig. 2h) and blastocyst-derived TS cells (Fig. 2i) were excluded from the ICM and found exclusively within the polar trophectoderm. For tracing ES-TS cell fate beyond the blastocyst stage, ES-TS cells were transduced with a GFP-expressing lentivirus 10 , injected into embryos and transferred into pseudopregnant foster mothers. At embryonic day 13.5 (E13.5), uninduced iRasES cells contributed widely to fetal tissues (Fig. 2j) , whereas progeny of the ES-TS cells were excluded from the embryo proper and found exclusively in the placenta (Fig. 2k,l) . These results suggest that ES-TS cells resemble TS cells in their ability to differentiate into trophoblastic cell lineages and reconstitute placental tissue during development. Notably, because the foster mothers were not fed doxycycline, the ES-TS cells did not generate tumors in the chimeric animals. Instead, the cells responded to the placental and fetal microenvironment of the developing embryo so that trophoblast cell growth and differentiation proceeded normally (Supplementary Note).
We set out to investigate the temporal relationship between Ras activation in ES cells and the expression of the cell-fate regulators Oct3/4 (ref. 11), Cdx2 (ref. 12) and Nanog 13 . The iRasES cells were plated on gelatin without mouse embryonic fibroblasts in four different media conditions: LIF, with and without doxycycline, and Fgf4 and heparin, with and without doxycycline. Addition of doxycycline led to marked induction of Ras protein expression within 6 h, which became maximal by 12 h (Fig. 3a) . The increase in Ras expression correlated with a marked decrease in Nanog and increase in Cdx2 expression, detectable after 12 h of culture (Fig. 3a) . These changes were dependent upon Ras expression, as culture in Fgf4 and heparin alone did not provoke changes in Cdx2 (Fig. 3a) . We also observed induction of Cdx2 and Hand1, another marker of trophectoderm, in two independent experimental contexts: in V6.5 ES cells expressing Hras1 Q61L from a retroviral vector, and in ES cells in which the Kras G12V Meso.
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allele was expressed at physiologic levels from the endogenous locus ( Supplementary Fig. 1 online) . Notably, the previously observed 14 reciprocal inhibition between Cdx2 and Oct4 was not recapitulated in our system. Within the first 24 h of Ras induction, the expression of Oct3/4 protein (Fig. 3a) and RNA (by microarray analysis; data not shown) remained unchanged. We therefore hypothesize that a reciprocal interaction between Cdx2 and Nanog might contribute to lineage segregation. Indeed, aberrant expression of Nanog can be found in the TE of Cdx2-deleted embryos 12 .
We engineered the Ainv15 ES cell line to conditionally express E-Ras, an ES-cell-specific Ras isoform (iE-RasES cells 15 ). E-Ras expression led to an increase in phosphoinositide-3 kinase (PI3K) activity, as measured by phosphorylation of p85Akt (pAkt), without altering MAPK activity, as measured by phosphorylation of Erk1/2 (pErk1/2; Fig. 3b ). In contrast, induction of the activated Hras1 Q61L allele in iRasES cells led to a marked increase of pErk1/2 and a modest increase in pAkt. In assays of tumor formation in immune-deficient mice, the iE-RasES cells formed larger teratomas when mice were fed doxycycline, but did not induce trophoblastic differentiation, whereas expression of a distinct activated allele of Hras1 (encoding G12V), known to signal through MAPK preferentially over PI3K, caused the hemorrhagic choriocarcinoma (Fig. 3c) . The induction of trophectoderm from ES cells thus seems to require signaling through the MAPK-Erk1/2 pathway rather than the PI3K pathway.
Induction of Hras1 Q61L is associated with changes in the expression of the transcription factors Cdx2 and Nanog (Fig. 3) . Consistently, inhibition of MAPK signaling with the inhibitor PD98059 maintained Nanog expression and blunted induction of Cdx2 expression (Fig. 3d) . Inhibitors of JNK, p38 and PI3K did not alter the induction of Cdx2 expression (data not shown). These data link Ras-MAPK signaling to the establishment or maintenance of trophectoderm, and provide a rationale for the common practice of including PD98095 in media used during ES cell derivation 16 , which is likely acting to suppress the outgrowth of trophectoderm from cultured blastocysts. In the mouse embryo, K-Ras and other small GTP-binding proteins are activated during the transition from the 8-cell stage to the morula 17 . Given our biochemical evidence that Ras-MAPK signaling can divert the fate of ES cells into trophectoderm, we investigated whether Ras-MAPK activity might be asymmetrically localized between the inner and outer cells of the embryo at the onset of morula compaction. We used an antibody specific for Erk2 to examine the temporal-spatial expression of this critical signaling intermediate in mouse embryos during the transition of blastomeres from morula to blastocyst. Confocal microscopy revealed polarized expression of Erk2 at the apical membrane of peripherally localized blastomeres at the 8-cell stage, whereas at later stages, Erk2 was distributed evenly throughout all cells of the morula and blastocyst (Fig. 4a) . This pattern contrasted with and was complementary to the basolateral expression of E-cadherin (Fig. 4b) , and is distinct from the pattern of b-catenin staining that appears uniform along both apical and basolateral membranes (Fig. 4b) . This asymmetric pattern of Erk2 localization at the 8-cell stage contrasts with the uniform distribution of Cdx2 and Nanog, which are detected equally in all blastomeres (Fig. 4c) . Only later, when embryos develop further to the morula stage, do the outer cells assume stronger Cdx2 expression, whereas the inner cells show stronger Nanog expression (Fig. 4c) . At the blastocyst stage, Cdx2 expression is restricted to the outer TE cells whereas Nanog is detected exclusively within the ICM (Fig. 4c) . Our observation of asymmetric Erk2 expression at the apical surface of the 8-cell mouse embryo, before the point at which blastomeres have adopted a clear fate, implicates Ras-MAPK signaling as a possible upstream effector of trophectoderm fate.
To test whether MAPK signaling could be functionally linked to trophectoderm formation, we investigated whether blockade of Erk2 signaling might compromise Cdx2 expression and alter embryo development in vitro. Treatment of 8-cell-stage embryos with the MAPK inhibitor PD98059 caused a loss of expression of Erk2 and phospho-Erk1/2 (p44/p42) ( Fig. 4d and Supplementary Fig. 2 online), and markedly attenuated Cdx2 expression within the morula and blastocyst (Fig. 4d-f) . The effects of MAPK inhibition were specific to Cdx2 expression, as the expression of Nanog and Nanogpositive cells was unaffected (Fig. 4e,f) . We observed that blockade of Ras-MAPK signaling is associated with a marked developmental delay of the embryos, as determined by progression to blastocele formation ( Table 1) . Of note, this effect requires exposure of the embryos at the 8-cell stage, when Erk2 signaling is asymmetrically localized. If the PD98059 compound is applied at the morula stage, no effect on Cdx2 expression or morula cavitation is observed (data not shown), suggesting a critical period for Erk2 action. The delay in blastocele formation was likewise accompanied by a decrease in the outgrowth of trophoblastic giant cells when PD908059-treated embryos were explanted into tissue culture ( Supplementary Fig. 3 online) . These data implicate Ras-MAPK signaling in maintaining the integrity and function of trophectoderm and in sustaining the outgrowth of trophoblastic elements in the developing mouse embryo.
We failed to observe defects in blastocyst formation when we treated mouse embryos with inhibitors of p38 JNK and PI3K (not shown). These results disagree with reports that blastocele formation is abrogated by JNK inhibition but not MAPK inhibition 18 . These apparent discrepancies may be due to our use of different embryo culture media (KSOM versus M2), different MAPK inhibitors (PD98059 versus U0126) or a different duration and timing of inhibitor administration. Moreover, prolonged treatment with U0126 can cause a compensatory induction of MAPK1 (Erk2) 19 . Ras-MAPK activation has been linked to Gata6 expression 20 and The effect of MAPK inhibition on the kinetics of blastocele formation is shown as the percentage and actual numbers of embryos (over total embryos in each culture condition) at different developmental stages after 24 h of in vitro culturing. Mouse embryos were treated from 8-cell stage and observed for the presence of blastoceles after 24 h.
primitive endoderm specification in the mouse embryo 21 . By titrating doxycycline dose, we explored the effect of varying levels of Ras expression on the induction of markers of trophectoderm and primitive endoderm. At low levels of Ras, the iRas ES cells express both trophectoderm markers Cdx2 and Hand1 as well as the primitive endoderm marker Gata6. At higher levels of Ras, trophectoderm markers predominated ( Supplementary Fig. 2 ). Therefore, it is likely that Ras-MAPK signaling has a role in two sequential developmental steps within the early mouse embryo: a position-dependent segregation of TE and ICM at the 8-cell-to-morula transition, and a positionindependent segregation of epiblast and hypoblast.
Our results demonstrate that Ras-MAPK signaling leads to transcriptional upregulation of Cdx2 within an hour. The trophectoderm specification factor Cdx2 is a phosphoprotein, but we have found no evidence that activation of Ras-MAPK signaling alters Cdx2 phosphorylation (data not shown). It is possible that Ras mediates Cdx2 upregulation through a cascade of transcription factors, such as Sp1/Sp3 and Ap2g. The Ap2g-deficient mouse embryo shows defects in trophectoderm and is completely devoid of Cdx2 expression 22 . Protein and RNA levels of Ap2g are rapidly elevated when Ras expression is induced in the iRas ES cells, supporting this hypothesis ( Supplementary Fig. 4 online) .
In mouse models, knockouts of Erk2 (ref. 23 ), Cdx2 (ref. 12) and Ap2g 22 show defects in ectoplacental cone formation and implantation, thereby implicating them as critical regulators of trophectoderm development. These genes are also expressed in the blastocyst, but their deficiency in these knockout models does not seem to compromise the specification of trophectoderm, perhaps because the early embryonic effects of these genes are mediated by maternal RNA. Analyzing these factors in complex maternal and zygotic knockouts is required to define their precise role in specifying the trophectoderm lineage. The actions of these genes behave differently than that of Tead4, an early onset zygotic transcript critical for TE formation 24 .
Although recent reports have suggested that developmental asymmetry may be initiated as early as the 4-cell stage of the cleaving mouse embryo 25 , the classical model holds that distinct cell fates are not irreversibly established until the 8-to 16-cell transition, which entail cleavages that yield daughter cells differing in size and identity 26, 27 . The opposing effect of Ras-MAPK and E-cadherin-b-catenin signaling is a well-defined mechanism for determining polarity in cultured epithelial cells 28 . The apical restriction of Erk2 in the 8-cell embryo in a pattern complementary to the basolateral distribution of E-cadherin and b-catenin (Fig. 4 and ref. 29 ) is similar to that of Par3, Par6 and aPKC, components of an apical polarity complex that has also been shown to influence TE-ICM fate choice 30 . Our data establish that activation of Ras-MAPK signaling can divert the fate of ES cells toward trophectoderm, and that blockade of Erk2 function in the mouse embryo compromises Cdx2 expression and blastocoele formation and delays embryo development. We cannot conclude with certainty that the apical localization of Erk2 within the 8-cell embryo is directly responsible for establishing the trophectoderm lineage, but our data, taken together with genetic models that implicate Erk2 and Ap2g in early placental function, further establish a role for Ras-MAPK signaling in promoting trophectoderm integrity and function in mouse development.
METHODS
Tumor pathology and animal care. Tumors and teratomas were obtained by subcutaneous injection of 1 million ES cells into Rag2 À/À ;gC À/À mice. Fixation, sectioning and staining were done by the Rodent Pathology Core Facility of the Harvard Medical School. A protocol for animal handling and maintenance in this study has been approved by the ARCH committee of the Children's Hospital Boston.
Cell culture. ES cells were cultured with 1000U/ml ESGRO, 15% FBS (Hyclone), 2 mM glutamine, penicillin and streptomycin, and 0.1 mM each of nonessential amino acids (Invitrogen). Blastocyst-derived TS cells were provided by J. Rossant and cultured in TS culturing media containing RPMI 1640, 20% serum (Hyclone), Fgf4 (25 ng/ml), heparin (1ng/ml), 100 mM b-mercaptoethanol, 1 mM sodium pyruvate, 2 mM glutamine, penicillin and streptomycin (Invitrogen).
Targeting constructs for generating inducible cell lines. We subcloned the HRas Q61L vector (Upstate) into the pLox vector. The mutation encoding G12V was introduced by the Quick-change mutagenesis kit (Stratagene) into the plox-HRasQ61L vector, and the mutation encoding Leu61 was changed back to wild-type (Gln61). E-Ras was amplified from cDNA of ES cells and cloned into the plox vector. All the plox constructs containing Ras mutants were verified by sequencing and subsequently transfected into Aniv15 cells by electroporation. We selected successfully targeted clones in G418 (300 mg/ml).
Embryo chimeras. Host embryos were obtained from C57BL/6 mice and were collected at the 2-cell stage. To observe chimerization at the blastocyst stage, we labeled B15 ES cells or ES-TS cells with pKH26 (Sigma) and injected them into the 4-to 8-cell stage embryo. After injection, the embryos were cultured in vitro in KSOM+AA (Specialty Media). For observation of chimerism in fetuses, 15 ES or ES-TS cells labeled with GFP by lentiviral vectors were injected into blastocyst stage embryos, followed by uterus transfer into pseudopregnant CD1 females.
RT-PCR for cell lineage analysis. Tumor samples were dissociated with 0.5% collagenase and processed in RNA-STAT. Total RNA was used to generate cDNA by amplification with random hexamers and RT-III reverse transcriptase (Invitrogen). cDNA was amplified for 28 cycles, with an annealing temperature of 48 1C. Primer sequences are listed in Supplementary Table 1 online.
Embryo collection, culture and staining. Mouse embryos were collected from CD1 mice (Charles River) that were superovulated by PMSG and HCG (7.5 IU each, Sigma). We also tested embryos from C57/B6 mice, but no apparent differences were observed. After removing cumulus cells (Hyaluronidase 0.03%, Sigma), embryos were collected at 1.5 dpc and incubated in KSOM+AA (Specialty Media) until different developmental stages. For MAPK inhibitor experiments, embryos were incubated in KSOM+AA containing 20 mM of PD98095 (Calbiochem) for 24 h before fixation and staining. 8-cell stage precompaction embryos (identified 24 h after collection of 2-cell embryos from oviducts) were assessed for the kinetics of blastocoele formation by incubation in KSOM+AA with or without 20 mM PD98095. Embryos were observed after an additional 24 h, and the number of embryos progressing to a particular stage was noted.
Whole-mount immunostaining was carried out as follows: embryos were fixed in 4% paraformaldehyde (20 min), permeabilized with 0.2% Triton X-100 (30 min), and blocked with 3% BSA/PBS (2 h), followed by binding of primary (overnight) and secondary antibodies (2 h). We used the following primary antibodies: anti-Cdx2 (Biogenex Mu392-UC, 1:50); anti-Nanog (Abcam Ab21603-100, 1:200); anti-pErk-2 (Cell Signaling Technology 9108, 1:1000); anti-phosphor-Erk1/2 (Cell Signaling Technology, 9106, 1:1000), antib-catenin (BD Pharmingen #610153, 1:1000) and anti-E-cadherin (BD Pharmingen #610182, 1:1000). We used Alexa Fluor 488 anti-mouse and Alexa Fluor 596 anti-rabbit secondary antibodies (Molecular Probe, A11029 and A11037). Epifluoresence microscopy was done on an inverted Leica microscope. The confocal images were captured using a Zeiss LSM510 Meta NLO laser scanning confocal microscope, consisting of a Zeiss Axioplan 2 upright microscope with Â10 (0.2 NA) dry objective, Â25 (0.75 NA) multi-imersion, Â40 (1.3 NA) oil, Â63 (1.4 NA) oil-immersion objective, a Melles Griot 50 mW 488/568/647 nm Kr/Ar multi-line laser, HE/NE lasers (543 and 633 nm) and a water-cooled two-photon laser (Chameleon, Coherent). A Fujitsu Seimens Scaleo 600 workstation was used for computer control of the system.
